Status:
COMPLETED
A Randomized Trial to Slow the Progression of Diabetes
Lead Sponsor:
Duke-NUS Graduate Medical School
Collaborating Sponsors:
National Medical Research Council (NMRC), Singapore
SingHealth Polyclinics
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
21-70 years
Phase:
NA
Brief Summary
The research objective of this one-year study is to test whether an evidence-based, low-cost mobile diabetes management package (DMP), with or without an incentive program grounded in economic theory ...
Detailed Description
Technological and economic advancement have created a major challenge to public health agencies in Singapore and other first world countries: the challenge being how to get individuals to maintain a h...
Eligibility Criteria
Inclusion
- All eligibility criteria will be self-declared.
- Diagnosed with T2DM with suboptimal diabetes control as defined by a HbA1c level of between 7.5% and 11.0% (inclusive) at their most recent test taken within the past six calendar months. This HbA1c inclusion criterion will be based on the patients' self-reported HbA1c levels and test dates.
- Not on insulin.
- On at least one oral glucose-lowering drug.
- Singapore Citizen or Permanent Resident with no plans to relocate during the study period.
- Able to read, write, and communicate in English.
- Own a personal smartphone and be able to use it.
Exclusion
- Pregnant or lactating.
- Diagnosed with chronic kidney disease (stage 3B with eGFR \<45mL/min) or undergoing dialysis for end-stage kidney failure.
- Diagnosed with liver cirrhosis.
- Diagnosed with cancer that required treatment in the past five years.
- Diagnosed with heart attack (i.e., acute myocardial infarction) within the past one year.
- Diagnosed with heart failure (i.e., congestive heart failure)
- Diagnosed with stroke or transient ischemic attacks.
- Undergone whole blood or red blood cell transfusion within the past three months.
- Diagnosed with severe anaemia (Haemoglobin \<10g/dL)
- Diagnosed with sickle-cell disease
- Diagnosed with Thalassemia major
- Undergone bariatric surgery or extensive bowel resection.
- Undergone lower limb amputation (including toe amputation).
- Taking systemic corticosteroids (including Traditional Chinese or Malay medicine).
- Currently on doctor's advice against engaging in moderate-to-vigorous physical activity (i.e., brisk walking or more intense).
- Currently have a condition(s) that restricts engaging in moderate-to-vigorous physical activity (i.e., brisk walking or more intense).
Key Trial Info
Start Date :
October 19 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 11 2023
Estimated Enrollment :
269 Patients enrolled
Trial Details
Trial ID
NCT03800680
Start Date
October 19 2019
End Date
June 11 2023
Last Update
June 22 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Duke-NUS Medical School
Singapore, Singapore, 169857